'Porphyria' has been derived from the ancient Greek word porphura, meaning purple. Porphyrins are precursors of heme, an essential component of hemoglobin. Each subunit of hemoglobin is a globular protein containing an embedded heme group that contains one iron atom, capable of binding one oxygen molecule. The heme synthesis pathway is a multi-step process that involves a specific enzyme at every step. Porphyrias are distinct clinical syndromes, which arise due to deficiency or defect in a particular enzyme needed for a specific step of the heme synthesis pathway. Although these syndromes have conventionally been classified depending on the predominant system involved (cutaneous vs. neurohepatic), significant overlap occurs, and many porphyrias present with mixed symptoms.
The clinical presentation, severity, and prognosis of individual porphyrias depend on which enzyme is deficient and the accumulation of the corresponding heme precursor or porphyrin. Acute intermittent porphyria (AIP) ranks as the most common and severe form of acute porphyria. Other acute porphyrias include hereditary coproporphyria (HCP), variegate porphyria (VP), and 5-aminolevulinic acid (ALA) dehydratase deficiency porphyria (Doss porphyria).
Similar to the majority of porphyrias, AIP shows an autosomal dominant pattern of inheritance. The acute porphyrias like AIP characteristically demonstrate acute episodes of neurovisceral symptoms, but may not manifest fully for a long time. AIP manifests as episodes of abdominal pain, neuropathies, and constipation, but, unlike the majority of other porphyrias, patients with AIP do not develop a cutaneous rash. The primary enzymatic defect in AIP is the deficiency of porphobilinogen-deaminase, also called hydroxymethylbilane synthase (HMBS), the third enzyme in heme synthesis. The acute attacks of AIP are a result of the uncontrolled upregulation of the ALA synthase enzyme. The diagnosis of AIP gets delayed due to nonspecific symptoms and similarities with other diseases. The only cure is orthoptic liver transplantation.
Acute intermittent porphyria results from mutations in the HMBS gene, which causes about 50% of HMBS deficiency. The gene is on the 11q24.1-q24.2 chromosome. For now, there are known 391 HMBS gene mutations. This deficiency is noticeable in the acute attacks, where the heme pool in the liver gets used, and there is the induction of delta-aminolevulinic acid synthase (ALAS1). This process leads to the accumulation of delta-aminolevulinic (ALA) and porphobilinogen (PBG), which are the immediate precursors proximal to the HMBS.
Inducers of acute attacks are alcohol, infections, low caloric intake, reproductive hormones change, and high-risk porphyrogenic drugs. The Norwegian Porphyria Centre (NAPOS), with the European Porphyria Network (Epnet), has created a list of medications that clinicians must avoid using in porphyria patients. These drugs include ketamine, thiopental, chloramphenicol, erythromycin, nitrofurantoin, rifampicin, trimethoprim/sulfamethoxazole, spironolactone, methyldopa, valproic acid, carbamazepine, phenytoin, phenobarbital, primidone, and risperidone.
Estimates of the combined prevalence of acute porphyrias are 5 cases per 10000 persons. Out of all these clinical syndromes, porphyria cutanea tarda (PCT) that has prominent cutaneous features is the most common porphyria, with an estimated prevalence of 1 in 10000. AIP, the most common acute porphyria, has an overall European prevalence of approximately 1 in 2000, with a higher incidence of 1 in 1000 in Sweden due to the founder effect. Recently, there are also reports of the founder effect correlating with a higher prevalence of AIP in certain ethnic groups in Argentina and Spain
Acute intermittent porphyria is a low-penetrant genetic metabolic disease with penetrance considered to be around 10 to 20% Excepting specific AIP populations, the penetrance of AIP in the general population has been estimated to be less than 1%. Manifest AIP (MAIP) is considered when carriers develop typical acute neurovisceral attacks with an elevation of porphyrin precursors. In the absence of clinical episodes, it is referred to as latent AIP (LAIP). Although higher penetrance has links to specific mutations, the overall genetic susceptibility factors underlying penetrance remain unknown.
Acute intermittent porphyria affects women to a greater degree than men, with a ratio of between 1.5 and 2 to 1. Attacks are rare before puberty. The typical age for the appearance of symptoms is between 18 to 40 years.
Acute attacks of acute intermittent porphyria are more frequent in women, especially in the post-pubertal age group. The acute attacks of AIP are typically triggered by certain factors, which include several drugs, infection, fasting, alcohol, steroid hormones, as stated above.
In acute intermittent porphyria, the neurologic damage occurs due to the accumulation of the porphyrin precursors, porphobilinogen, and aminolevulinic acid (ALA). The AIP-associated neurological damage manifests as peripheral, and autonomic neuropathies, and psychiatric manifestations.
The exact mechanism by which elevated levels of porphobilinogen and ALA lead to symptomatic disease remains enigmatic because most patients with the genetic defect do not present with symptoms despite excessive porphyrin secretion.
A recent (2017) case-control study in 50 patients reported the association of acute intermittent porphyria with systemic inflammation. Storjord et al. found that the levels of insulin, C-peptide, prealbumin, and markers of kidney function, were decreased in symptomatic patients only, sparing the asymptomatic ones. They postulated that in symptomatic patients of AIP, reduced insulin release is associated with enhanced disease activity and compromised kidney function.
Acute attacks of acute intermittent porphyria usually last for up to a week.
The symptoms progress as follows : Abdominal pain, then psychiatric symptoms and finally peripheral neuropathies.
The abdominal pain is typically severe, epigastric, and colicky. It tends to last for several days. It can be associated with constipation and vomiting.
Patients can present with a broad spectrum of psychiatric symptoms, such as depression, which are accompanied by concurrent abdominal and/or neurologic symptoms. A study conducted in Sweden demonstrated an increased risk of schizophrenia or bipolar disorder in patients with AIP, as well as in their relatives. 
Peripheral neuropathies can manifest as a weakness that begins in the lower extremities and ascends, although any nerve distribution may be affected. This presentation can mimic Guillain-Barre syndrome (GBS). Hypertension and tachycardia secondary to autonomic neuropathies can also occur.
Central nervous system signs may include delirium, weakness with progression to quadriplegia and respiratory failure, cortical blindness, and even coma. In 5% of cases, patients can develop seizures, with partial seizures being the most common subtype. Sometimes red or brown urine may be observed, which darkens on exposure to air, light, and warmth. It is important to note that unlike porphyria cutanea tarda, AIP does not have any cutaneous manifestations.
In conventional terms, patients have been reported to be completely free of symptoms in between the attacks. But it is also suggested than 20 to 64% of patients may suffer from disabling chronic manifestations such as pain, nausea, fatigue, and neuropathic features, including numbness and tingling sensations.
The diagnosis of acute intermittent porphyria results from finding elevated PBG in urine in a random sample kept protected from light. Diagnostic confirmation should be with a quantitative measurement of PBG, ALA, and total porphyrins from the same urine sample. Normal values are 0 to 4 mg/L, but during an acute attack of AIP, values may reach as high as 25 to 100 mg of ALA and 50 to 200 mg of PBG.
A urinary PBG level of only 0 to 4 mg/L during acute symptoms almost rules out acute porphyria as the cause of neurovisceral symptoms.
Although urine collection for quantification of PBG and ALA is optimal during the peak of an attack of AIP, it may be collected within a few days to weeks after the acute episode also, owing to the persistent elevation of urinary ALA and PBG for many months to years after an attack. The only exception to this leniency is the timed collection of urine, which arises if the patient has received treatment with a 4- to 5-day course of intravenous heme.
Elevation of urine porphyrins, especially copro porphobilinogen (caused by spontaneous polymerization of porphobilinogen in the urine) is often observable. However, it merits noting that the nonspecific elevation of urine porphyrins, especially coproporphyrins (1 to 2 times the reference range) is common and not specific for porphyria. Stool porphyrins are typically within the reference range or just mildly elevated.
An increase in plasma porphyrin confirmed by increased fluorescence emission scan peak at 619 nm can present. Molecular and DNA testing of HMBS deficiency is not necessary for the diagnosis, but has utility for family screening.
ASSOCIATED LABORATORY ABNORMALITIES (DURING AN ACUTE ATTACK):
DIFFERENTIATING BETWEEN ACUTE PORPHYRIAS
As mentioned below (vide infra), the symptomatology of most of the acute porphyrias shows significant overlap. Symptoms of AIP are often clinically indistinguishable from those of hereditary coproporphyria and variegate porphyria. Although the diagnostic approach to distinguish AIP from other acute porphyrias has little evidence backing at present, new evidence-based diagnostic strategies are under development for these conditions.
Plasma Fluorescence Staining
In contrast to AIP, HCP and other porphyrias in which the sera of subjects with biochemically active disease have emission peaks at approximately 619 nm to 620 nm, the serum from patients with VP have a unique porphyrin-peptide in plasma that has its peak fluorescence at approximately 626 nm, following excitation by light of 410 nm (the Soret band). This reaction forms the basis of the utility of fluorescence of diluted sera at physiologic pH to differentiate VP from other acute as well as cutaneous porphyrias.
Emerging Role of Genetic Mutation Analysis in Diagnostic Confirmation
The specific type of acute porphyria is now discernable by genetic testing, which is available commercially at several labs. The approach involves sequencing of the four genes that are defective in the acute porphyrias :
Gene/Type of Acute Porphyria
ALAD/ALAD-deficient porphyria (Doss porphyria)
The evolution of next-generation sequencing (NGS) to porphyria diagnosis is ongoing with investigators having recently designed a panel containing four genes - ALAS1, HMBS, CPOX, and PPOX for mutational analysis of AIP, HCP, and VP.
INITIAL AND SYMPTOM-ORIENTED TREATMENT
Owing to the simulation of symptoms of acute intermittent porphyria by several abdominal, metabolic, and neuropsychiatric conditions, establishing a confirmed diagnosis forms the core of the management of AIP.
Avoidance of precipitants, especially drugs, requires extreme emphasis, ingraining it in the patient and relatives' psyche. (vide infra)
When a patient with confirmed AIP presents with an acute attack, the usual first approach is to load the patient with a high carbohydrate diet or intravenously administered dextrose to inhibit hepatic ALAS1 transcription. Administration of 10% dextrose in 0.45% saline should start immediately. If the patient does not present with weakness, vomiting or hyponatremia, a trial of a high carbohydrate diet for 48 hours before starting specific treatment is the current recommendation.
For pain, parenteral opiates are the best option (morphine, diamorphine, and fentanyl). Nausea and vomiting are controllable with prochlorperazine, promazine, and ondansetron. These symptoms usually start abating in 72 to 96 hours. For tachycardia and hypertension, preferred medications are beta-blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers (diltiazem). If the patient presents with seizures, they are controllable with diazepam, magnesium sulfate, or clonazepam.
Intravenous administration of heme is the specific therapy. It replenishes the hepatocyte heme pool and down-regulates ALAS1, resulting in reduced production of porphyrin precursors and corresponding improvement in symptoms . Heme not only controls hepatic ALAS1 by down-regulating ALAS1 transcription but also by inducing mRNA destabilization or by blocking the mitochondrial import of the mature enzyme.
Owing to the delayed effect of heme therapy on reducing plasma ALA and PBG level, intravenous heme therapy (IHT) should be administered without delay in severe acute attacks and maintained for four days (3 to 4 mg/kg of heme/day). A response usually appears on the third day with a decrease of urine and serum PBG. Panhematin administration should be through a large peripheral vein or central line due to the risk of phlebitis in small veins, a risk also reduced by preparing it with human albumin instead of water. Other complications are an increase in prothrombin time during the first 2 hours and increased iron production in the liver. Patient discharge can take place when parenteral opioids can stop, and they can tolerate oral drugs.
Excepting occasional complaints of headache or pyrexia, IHT is well tolerated. However, there are inherent risks associated with recurrent treatments with IHT, of which every caregiver should be cognizant.
RISKS ASSOCIATED WITH RECURRENT IHT
The following enumerates the significant issues associated with recurrent IHT - the need to replace the venous access to prevent thromboembolic disease, risk of liver fibrosis, hepatic iron overload, and development of therapeutic 'tolerance' to heme infusion. Research has shown that heme infusion can induce the expression of hepatic heme oxygenase 1 (HMOX1, EC 220.127.116.11, HGNC: 5013). HMOX1 is the crucial enzyme of heme catabolism. Its induction by heme therapy results in the reduction of hepatocyte heme pool and consequently enhanced expression of ALAS1. This heme-induced auto-catabolic effect generates the tolerance reported in some patients.
Currently, the only established cure for acute intermittent porphyria is orthotopic liver transplantation (OLT) with a reported survival rate of around 80%. However, a high risk (40%) of hepatic artery thrombosis with OLT prompted the same authors to recommend reserving the procedure for patients with severe recurrent acute attacks and highly impaired quality of life (QoL).
Some studies are looking for other alternatives. These are in different phases of clinical trials, and in this CME chapter at present, only seeks to inform the readers of these potential and futuristic therapies:
POTENTIAL/EXPERIMENTAL THERAPIES FOR AIP
Enzyme Replacement Therapy [ERT] - Based on the experience of administering doses of recombinant human HMBS/PBGD (rhPBGD) protein in a mouse model of AIP that reduced plasma PBG accumulation during an acute attack induced after phenobarbital challenge, in 2002 the European Medicines Agency (EMA) granted recombinant human HMBS/PBGD an orphan designation (EU/3/ 02/103). Researchers conducted clinical trials in healthy subjects, asymptomatic HMBS-deficient subjects with increased porphyrin precursor excretion and AIP patients with repeated attacks. Although the enzyme was able to detoxify PBG metabolites, the treatment approach limitations included its short half-life in circulation and the lack of liver targeting.
Liver Gene Therapy - Clinical trials using two strategies, HMBS-gene therapy and interference RNA for ALAS1 gene inhibition, are being conducted in patients with AIP. The two strategies include - the delivery of the HMBS gene to the hepatocytes using a viral vector. The other option is a small interfering RNA (siRNA) directed against aminolevulinic acid synthase, with the objective of reducing delta ALA production. Both of them are still in the trial phase and await approval, pending larger trials that would hopefully provide consistent efficacy and safety.
In an observational study of acute porphyrias, which included 90 patients with AIP, researchers found that the diagnostic delay was a mean of 15 years. The predominance of the acute abdomen as the presenting symptom of an acute attack of AIP, patients often undergo appendectomies or cholecystectomies before the diagnosis of porphyria is suspected and/or confirmed.
Owing to the broad spectrum neuro-visceral clinical presentation of AIP, the list of differential diagnosis is long:
Prognosis is good if acute intermittent porphyria is recognized early and treated at the time. The mortality has decreased through the past decades to 5 to 20% (on acute attacks) thanks to new methods of diagnosis and treatment. But if the disease is resistant to heme therapy and is recurrent the only currently approved way to reduce mortality is with an orthotopic liver transplant.
With ongoing trials exploring the efficacy and safety of ERT and liver gene therapy, the prognosis of AIP is expected to become better very soon.
Complications of acute intermittent porphyria (vide infra); arterial hypertension, chronic kidney disease, neurologic deficits, and risk of hepatocellular carcinoma must remain in check by ensuring close observation and review of the patient.
AIP is a rare autosomal dominant condition that runs a chronic course with recurrent acute episodes of neurovisceral symptoms. Trials are giving hope to find a definitive cure to this life -long disease. Once the diagnosis of AIP or some other acute hepatic porphyria is confirmed, patients should be thoroughly counseled and provided with the list of trigger factors (that can precipitate an attack) for avoidance, especially drugs that are safe and unsafe. They should know that treatment is only available for acute attacks and that the best way to remain asymptomatic is by preventing precipitants. If they have abdominal pain should go immediately to the emergency department. They should receive education on prognosis and complications and strongly encouraged to obtain genetic testing done for their offspring.
Clinicians should suspect acute intermittent porphyria should in patients with abdominal pain, and symptoms or signs suggestive of neuropsychiatric morbidity. A patient with a purely medical ailment often ends up with the surgeons due to recurrent acute abdomen and may undergo unnecessary surgeries. Thus, the surgical team should be aware of this non-surgical cause of severe acute abdomen and maintain a high index of suspicion in a patient with recurrent attacks or one who presents with additional neuropsychiatric symptoms.
Interprofessional involvement of the primary care physician, nurse practitioner, metabolic/genetic disease expert, hematologist, biochemist, pharmacist, nursing, and the surgeon is essential to diagnose the disease early to limit the long-term complications of the patient. Lastly, the involvement of clinical geneticists for genetic counseling regarding the conception of a child by a patient with AIP is paramount to discuss the risk of acquisition, prenatal testing and other aspects of prevention and/or early identification of AIP carrier state in the offspring. Nursing will be responsible for heme therapy administration and should monitor therapy progress as well as any adverse reactions, and inform the clinician should there be an issue. Pharmacists should verify dosing, as well as perform medication review to scan both for drug interactions, as well as drugs that can precipitate porphyria attacks, reporting any concerns to the team physicians managing the case. Open communication and collaboration between interprofessional members of the team are essential if one wants to avoid the high morbidity of this disorder. [Level V]
|||Wang B,Rudnick S,Cengia B,Bonkovsky HL, Acute Hepatic Porphyrias: Review and Recent Progress. Hepatology communications. 2019 Feb; [PubMed PMID: 30766957]|
|||Pischik E,Kauppinen R, An update of clinical management of acute intermittent porphyria. The application of clinical genetics. 2015; [PubMed PMID: 26366103]|
|||Fontanellas A,Ávila MA,Berraondo P, Emerging therapies for acute intermittent porphyria. Expert reviews in molecular medicine. 2016 Nov 2; [PubMed PMID: 27804912]|
|||Szlendak U,Bykowska K,Lipniacka A, Clinical, Biochemical and Molecular Characteristics of the Main Types of Porphyria. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2016 Mar-Apr; [PubMed PMID: 27627571]|
|||Roveri G,Nascimbeni F,Rocchi E,Ventura P, Drugs and acute porphyrias: reasons for a hazardous relationship. Postgraduate medicine. 2014 Nov; [PubMed PMID: 25387219]|
|||Ramanujam VM,Anderson KE, Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias. Current protocols in human genetics. 2015 Jul 1; [PubMed PMID: 26132003]|
|||Cerbino GN,Gerez EN,Varela LS,Melito VA,Parera VE,Batlle A,Rossetti MV, Acute intermittent porphyria in Argentina: an update. BioMed research international. 2015 [PubMed PMID: 26075277]|
|||Puy H,Gouya L,Deybach JC, Porphyrias. Lancet (London, England). 2010 Mar 13 [PubMed PMID: 20226990]|
|||Chen B,Solis-Villa C,Hakenberg J,Qiao W,Srinivasan RR,Yasuda M,Balwani M,Doheny D,Peter I,Chen R,Desnick RJ, Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease. Human mutation. 2016 Nov [PubMed PMID: 27539938]|
|||Storjord E,Dahl JA,Landsem A,Fure H,Ludviksen JK,Goldbeck-Wood S,Karlsen BO,Berg KS,Mollnes TE,W Nielsen E,Brekke OL, Systemic inflammation in acute intermittent porphyria: a case-control study. Clinical and experimental immunology. 2017 Mar [PubMed PMID: 27859020]|
|||Whatley SD,Badminton MN, Acute Intermittent Porphyria 1993; [PubMed PMID: 20301372]|
|||Cederlöf M,Bergen SE,Larsson H,Landén M,Lichtenstein P, Acute intermittent porphyria: comorbidity and shared familial risks with schizophrenia and bipolar disorder in Sweden. The British journal of psychiatry : the journal of mental science. 2015 Dec [PubMed PMID: 26494868]|
|||O'Malley R,Rao G,Stein P,Bandmann O, Porphyria: often discussed but too often missed. Practical neurology. 2018 Oct; [PubMed PMID: 29540448]|
|||Simon A,Pompilus F,Querbes W,Wei A,Strzok S,Penz C,Howe DL,Hungate JR,Kim JB,Agarwal S,Marquis P, Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations. The patient. 2018 Oct [PubMed PMID: 29915990]|
|||Marsden JT,Rees DC, Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria. Journal of clinical pathology. 2014 Jan [PubMed PMID: 23908454]|
|||Ventura P,Cappellini MD,Biolcati G,Guida CC,Rocchi E, A challenging diagnosis for potential fatal diseases: recommendations for diagnosing acute porphyrias. European journal of internal medicine. 2014 Jul; [PubMed PMID: 24809927]|
|||Besur S,Schmeltzer P,Bonkovsky HL, Acute Porphyrias. The Journal of emergency medicine. 2015 Sep; [PubMed PMID: 26159905]|
|||Bonkovsky HL,Guo JT,Hou W,Li T,Narang T,Thapar M, Porphyrin and heme metabolism and the porphyrias. Comprehensive Physiology. 2013 Jan [PubMed PMID: 23720291]|
|||Barman-Aksözen J,Suter L,Wegmann F,Meienberg J,Minder AE,Beer M,Komminoth P,Minder EI,Schneider-Yin X, A next-generation-sequencing panel for mutational analysis of dominant acute hepatic porphyrias. Scandinavian journal of clinical and laboratory investigation. 2019 Sep [PubMed PMID: 31154864]|
|||Bissell DM,Anderson KE,Bonkovsky HL, Porphyria. The New England journal of medicine. 2017 Aug 31; [PubMed PMID: 28854095]|
|||Aarsand AK,Petersen PH,Sandberg S, Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Clinical chemistry. 2006 Apr [PubMed PMID: 16595824]|
|||Willandt B,Langendonk JG,Biermann K,Meersseman W,D'Heygere F,George C,Verslype C,Monbaliu D,Cassiman D, Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series. JIMD reports. 2016 [PubMed PMID: 26093628]|
|||Goetsch CA,Bissell DM, Instability of hematin used in the treatment of acute hepatic porphyria. The New England journal of medicine. 1986 Jul 24 [PubMed PMID: 3724815]|
|||Doberer D,Haschemi A,Andreas M,Zapf TC,Clive B,Jeitler M,Heinzl H,Wagner O,Wolzt M,Bilban M, Haem arginate infusion stimulates haem oxygenase-1 expression in healthy subjects. British journal of pharmacology. 2010 Dec [PubMed PMID: 20718734]|
|||Dover SB,Moore MR,Fitzsimmons EJ,Graham A,McColl KE, Tin protoporphyrin prolongs the biochemical remission produced by heme arginate in acute hepatic porphyria. Gastroenterology. 1993 Aug [PubMed PMID: 8335204]|
|||Yasuda M,Erwin AL,Liu LU,Balwani M,Chen B,Kadirvel S,Gan L,Fiel MI,Gordon RE,Yu C,Clavero S,Arvelakis A,Naik H,Martin LD,Phillips JD,Anderson KE,Sadagoparamanujam VM,Florman SS,Desnick RJ, Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver. Molecular medicine (Cambridge, Mass.). 2015 Jun 5 [PubMed PMID: 26062020]|
|||Dowman JK,Gunson BK,Mirza DF,Bramhall SR,Badminton MN,Newsome PN, Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2012 Feb [PubMed PMID: 21618697]|
|||Johansson A,Möller C,Fogh J,Harper P, Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement. Molecular medicine (Cambridge, Mass.). 2003 Sep-Dec [PubMed PMID: 15208740]|
|||Sardh E,Rejkjaer L,Andersson DE,Harper P, Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clinical pharmacokinetics. 2007 [PubMed PMID: 17375984]|
|||Prieto J,Gonzalez-Aseguinolaza G, Acute Intermittent Porphyria: Novel Etiologic and Pathogenic Therapies Based on RNA Transfer to the Liver. Hepatology (Baltimore, Md.). 2019 Apr 26; [PubMed PMID: 31026336]|
|||Bonkovsky HL,Maddukuri VC,Yazici C,Anderson KE,Bissell DM,Bloomer JR,Phillips JD,Naik H,Peter I,Baillargeon G,Bossi K,Gandolfo L,Light C,Bishop D,Desnick RJ, Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. The American journal of medicine. 2014 Dec [PubMed PMID: 25016127]|
|||Pallet N,Mami I,Schmitt C,Karim Z,François A,Rabant M,Nochy D,Gouya L,Deybach JC,Xu-Dubois Y,Thervet E,Puy H,Karras A, High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney international. 2015 Aug [PubMed PMID: 25830761]|
|||Sardh E,Andersson DE,Henrichson A,Harper P, Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cellular and molecular biology (Noisy-le-Grand, France). 2009 Feb 16 [PubMed PMID: 19268004]|
|||[PubMed PMID: 22851509]|
|||Bissell DM,Anderson KE,Bonkovsky HL, Porphyria. The New England journal of medicine. 2017 Nov 23; [PubMed PMID: 29166231]|